化学科研者一站式服务平台


  • 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉-4(3H)-酮

    2-(4-(2-Hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one

化合物简介

RVX 208 (RVX-208) is an orally available small molecule created by Resverlogix Corp. that is being evaluated in clinical trials for the treatment of atherosclerosis and associated cardiovascular disease (CVD). In two phase II clinical trials in patients with established CVD, RVX-208 increased HDL-cholesterol (HDL-c) and apolipoprotein A-I (ApoA-I) levels, as well as decreased the incidence of major adverse cardiac events (MACE). Reduction of MACE was accentuated in patients with diabetes mellitus.

基本信息

CAS:1044870-39-4
中文别名:2-[3,5-二甲基-4-(2-羟基乙氧基)苯基]-5,7-二甲氧基喹唑啉-4(3H)-酮;
英文别名:2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1H-quinazolin-4-one;
分子式:C20H22N2O5
分子量:370.399
精确质量:370.153
Psa:93.67
Logp:2.5952

编号系统

MDL号:MFCD18633270

物化性质

密度:1.3±0.1g/cm3
外观性状:白色至黄色固体
折射率:1.596
储存条件:-20℃

安全信息

海关编码:2933990090

生产方法及用途

合成路线

上游原料

下游产品

图谱

13C NMR : Predict


1H NMR : Predict


加载中...